{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:36:16Z","timestamp":1790451376813,"version":"4.1.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Venetoclax (VEN), a B-cell lymphoma 2 (BCL2) inhibitor, has a promising single-agent activity in mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and large BCLs, but remissions were generally short, which call for rational drug combinations. Using\u00a0a panel of 21 lymphoma and leukemia cell lines and 28 primary samples, we demonstrated strong synergy between VEN and A1155463, a BCL-XL inhibitor. Immunoprecipitation experiments and studies on clones with knockout of expression or transgenic expression of BCL-XL confirmed its key role in mediating inherent and acquired VEN resistance. Of note, the VEN and A1155463 combination was synthetically lethal even\u00a0in the cell lines with lack of expression of the proapoptotic BCL2L11\/BIM and in the derived clones with genetic knockout of BCL2L11\/BIM. This is clinically important because BCL2L11\/BIM deletion, downregulation, or sequestration results in VEN resistance. Immunoprecipitation experiments further suggested that the proapoptotic effector BAX belongs to principal mediators of the VEN and A1155463 mode of action in the BIM-deficient cells. Lastly, the efficacy of the new proapoptotic combination was confirmed in\u00a0vivo on a\u00a0panel of 9 patient\u2013derived lymphoma xenografts models including MCL (n\u00a0= 3), B-ALL (n\u00a0=\u00a02), T-ALL (n\u00a0= 1), and diffuse large BCL (n\u00a0= 3). Because continuous inhibition of BCL-XL causes thrombocytopenia, we proposed and tested an interrupted 4\u00a0days on\/3\u00a0days off treatment regimen, which retained the desired antitumor synergy with manageable platelet toxicity. The proposed VEN and A1155463 combination represents an innovative chemotherapy-free regimen with significant preclinical activity across diverse BCL2+ hematologic malignancies irrespective of the BCL2L11\/BIM status.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012906","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T19:54:37Z","timestamp":1715111677000},"page":"3532-3543","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5982-6523","authenticated-orcid":false,"given":"Alexandra","family":"Dolnikova","sequence":"first","affiliation":[{"name":"1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5660-8080","authenticated-orcid":false,"given":"Dmitry","family":"Kazantsev","sequence":"additional","affiliation":[{"name":"1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Klanova","sequence":"additional","affiliation":[{"name":"1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic"},{"name":"2First Department of Medicine, Department of Hematology, Charles University General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0747-4623","authenticated-orcid":false,"given":"Eva","family":"Pokorna","sequence":"additional","affiliation":[{"name":"1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-5912","authenticated-orcid":false,"given":"Dana","family":"Sovilj","sequence":"additional","affiliation":[{"name":"3Institute of Biotechnology Czech Academy of Sciences\/Biotechnology and Biomedicine Centre of the Czech Academy of Sciences and Charles University, Vestec, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Daniela","family":"Kelemen","sequence":"additional","affiliation":[{"name":"3Institute of Biotechnology Czech Academy of Sciences\/Biotechnology and Biomedicine Centre of the Czech Academy of Sciences and Charles University, Vestec, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Tuskova","sequence":"additional","affiliation":[{"name":"1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic"},{"name":"2First Department of Medicine, Department of Hematology, Charles University General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7185-6119","authenticated-orcid":false,"given":"Eva","family":"Hoferkova","sequence":"additional","affiliation":[{"name":"4Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic"},{"name":"5Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Mraz","sequence":"additional","affiliation":[{"name":"4Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic"},{"name":"5Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7141-8074","authenticated-orcid":false,"given":"Karel","family":"Helman","sequence":"additional","affiliation":[{"name":"6Faculty of Informatics and Statistics, University of Economics, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Curik","sequence":"additional","affiliation":[{"name":"7Institute of Hematology and Blood Transfusion, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Machova Polakova","sequence":"additional","affiliation":[{"name":"7Institute of Hematology and Blood Transfusion, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Andera","sequence":"additional","affiliation":[{"name":"3Institute of Biotechnology Czech Academy of Sciences\/Biotechnology and Biomedicine Centre of the Czech Academy of Sciences and Charles University, Vestec, Czech Republic"},{"name":"8Institute of Molecular Genetics CAS, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[{"name":"2First Department of Medicine, Department of Hematology, Charles University General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-9378","authenticated-orcid":false,"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[{"name":"1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic"},{"name":"2First Department of Medicine, Department of Hematology, Charles University General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"issue":"4","key":"2024070913154063200_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024070913154063200_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"2024070913154063200_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024070913154063200_bib4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2024070913154063200_bib5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood.2020006578","article-title":"A\u00a0phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"17","key":"2024070913154063200_bib6","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024070913154063200_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-022-00621-9","article-title":"Venetoclax-ponatinib for T315I\/compound-mutated Ph+ acute lymphoblastic leukemia","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024070913154063200_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41375-022-01746-3","article-title":"Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy","volume":"37","author":"Cheung","year":"2023","journal-title":"Leukemia"},{"issue":"13","key":"2024070913154063200_bib9","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/bloodadvances.2022008916","article-title":"A\u00a0multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma","volume":"7","author":"Sawalha","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2024070913154063200_bib10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2024070913154063200_bib11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2024070913154063200_bib12","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41375-023-01879-z","article-title":"Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic venetoclax resistance","volume":"37","author":"Nakao","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2024070913154063200_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"2024070913154063200_bib14","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat Commun"},{"issue":"14","key":"2024070913154063200_bib15","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv"},{"issue":"7","key":"2024070913154063200_bib16","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"2024070913154063200_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"14","key":"2024070913154063200_bib18","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","article-title":"Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in\u00a0vivo in relapsed mantle cell lymphoma","volume":"25","author":"Prukova","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024070913154063200_bib19","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A\u00a0novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"2024070913154063200_bib20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"key":"2024070913154063200_bib21","doi-asserted-by":"crossref","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"issue":"7626","key":"2024070913154063200_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"27 2016","journal-title":"Nature"},{"issue":"12","key":"2024070913154063200_bib23","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"2024070913154063200_bib24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Genes Dev"},{"issue":"2","key":"2024070913154063200_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.22664","article-title":"Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes","volume":"49","author":"Vick","year":"2009","journal-title":"Hepatology"},{"key":"2024070913154063200_bib26","doi-asserted-by":"crossref","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"25","key":"2024070913154063200_bib27","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2024070913154063200_bib28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41419-021-04042-7","article-title":"Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2\/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2\/STAT3\/MCL-1 signaling pathway","volume":"12","author":"Luo","year":"2021","journal-title":"Cell Death Dis"},{"key":"2024070913154063200_bib29","doi-asserted-by":"crossref","first-page":"100798","DOI":"10.1016\/j.neo.2022.100798","article-title":"Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2\/Bcl-X(L) dual inhibitor that induces Bax-dependent apoptosis","volume":"29","author":"Yao","year":"2022","journal-title":"Neoplasia"},{"issue":"24","key":"2024070913154063200_bib30","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","article-title":"AZD4320, a dual inhibitor of Bcl-2 and Bcl-x(L), induces tumor regression in hematologic cancer models without dose-limiting thrombocytopenia","volume":"26","author":"Balachander","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2024070913154063200_bib31","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41374-022-00784-w","article-title":"Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas","volume":"102","author":"Jak\u0161a","year":"2022","journal-title":"Lab Invest"},{"issue":"3","key":"2024070913154063200_bib32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","article-title":"Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL","volume":"130","author":"Erdmann","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2024070913154063200_bib33","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ng.343","article-title":"Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates","volume":"41","author":"M\u00e1t\u00e9s","year":"2009","journal-title":"Nat Genet"},{"issue":"6121","key":"2024070913154063200_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science (New York, NY)"},{"issue":"1","key":"2024070913154063200_bib35","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"issue":"6","key":"2024070913154063200_bib36","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/1878-0261.13364","article-title":"JAK-STAT signalling shapes the NF-\u03baB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL","volume":"17","author":"Haselager","year":"2023","journal-title":"Mol Oncol"},{"issue":"5","key":"2024070913154063200_bib37","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","article-title":"Regulation of Bcl-XL by non-canonical NF-\u03baB in the context of CD40-induced drug resistance in CLL","volume":"28","author":"Haselager","year":"2021","journal-title":"Cell Death Differ"},{"issue":"1","key":"2024070913154063200_bib38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Del Gaizo Moore","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2024070913154063200_bib39","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"17","key":"2024070913154063200_bib40","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2024070913154063200_bib41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2024070913154063200_bib43","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024070913154063200_bib44","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"7","key":"2024070913154063200_bib45","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3390\/biom10071081","article-title":"DLBCL cells with acquired resistance to venetoclax are not sensitized to BIRD-2 but can be resensitized to venetoclax through Bcl-XL inhibition","volume":"10","author":"Kerkhofs","year":"2020","journal-title":"Biomolecules"},{"issue":"12","key":"2024070913154063200_bib46","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3390\/cancers11121827","article-title":"FLT3-ITD activates RSK1 to enhance proliferation and survival of AML cells by activating mTORC1 and eIF4B cooperatively with PIM or PI3K and by inhibiting Bad and BIM","volume":"11","author":"Watanabe","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"2024070913154063200_bib47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","article-title":"Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas","volume":"109","author":"Mestre-Escorihuela","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2024070913154063200_bib48","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/sj.onc.1208300","article-title":"Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM","volume":"24","author":"Tagawa","year":"2005","journal-title":"Oncogene"},{"issue":"26","key":"2024070913154063200_bib49","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3532\/2233833\/blooda_adv-2024-012906-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3532\/2233833\/blooda_adv-2024-012906-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:16:20Z","timestamp":1720530980000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3532\/516030\/Blockage-of-BCL-XL-overcomes-venetoclax-resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":48,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012906","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}